Novel Nanostructures for Topical Photodynamic Therapy
用于局部光动力治疗的新型纳米结构
基本信息
- 批准号:7474646
- 负责人:
- 金额:$ 40万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-08-01 至 2011-01-31
- 项目状态:已结题
- 来源:
- 关键词:AccountingAcneAerosolsAffectAftercareAgreementAmericanAnimal ModelAntibiotic ResistanceAntimicrobial ResistanceArchitectureAreaAttentionBacteriaBacterial InfectionsBindingBiologicalBurn TraumaBurn injuryCandida albicansCandidiasisCarbonCell NucleusCell WallCellsClassClinicalCollaborationsCommunicable DiseasesConditionDataDentistryDermatologyDevelopmentDisclosureDiseaseEscherichia coliEvaluationFocal InfectionFullerenesGeneral HospitalsGoalsGovernmentGram-Negative BacteriaGram-Positive BacteriaHistocompatibility TestingImageInfectionInfectious AgentInjection of therapeutic agentIntellectual PropertyInvasiveInvestigationIsomerismLaboratoriesLasersLeadLegal patentLettersLightLightingLocalizedMammalian CellManufacturer NameMarketingMassachusettsMediationMedicalMembraneMethodsMicrobeMycosesNail plateNanostructuresNormal CellNumbersOphthalmologyOutcomePermeabilityPersonsPhasePhase I Clinical TrialsPhase II Clinical TrialsPhotochemotherapyPhotosensitizing AgentsPorphyrinsPositioning AttributePredispositionProceduresProcessPropertyPseudomonas aeruginosaPurposeRangeReactive Oxygen SpeciesResearchRoleRouteSinglet OxygenSkinSourceStructureSurgical incisionsTechniquesTestingTetrapyrrolesTimeTissuesTolonium chlorideTopical applicationTrademarkTreatment EfficacyUnited StatesVisible RadiationWound Infectionantimicrobialauthoritybacteriochlorinbasebiomaterial compatibilitycancer cellcancer therapycationic fullerenecell typechlorincommercializationcostcytotoxicitydesignfullerene C60functional groupfungusinterstitialkillingsmedical schoolsmicrobialmicroorganismmouse modelnanomaterialsnanoscalenovelpathogenic bacteriaphthalocyaninepre-clinicalresearch and developmentscaffoldsizetherapy developmenttumoruptakewater solubility
项目摘要
DESCRIPTION (provided by applicant): Fullerenes are a class of closed-cage nanomaterials comprised exclusively of carbon atoms. A great deal of attention has been focused on developing medical uses of these unique molecules. This proposal concerns the development of fullerenes in antimicrobial photodynamic therapy, a non-invasive procedure that combines a non-toxic photosensitizer with harmless visible light to kill microbial cells. An advantage of photodynamic therapy is its high level of selectivity. This is achieved by using photosensitizers that selectively target specific cell types and by controlling the area that is illuminated. In the Phase I study, a number of fullerene-based photosensitizers with highly desirable properties were synthesized and tested. The PS inactivated a broad spectrum of microbes (6 log reduction of gram positive bacteria, gram negative bacteria and fungi). The Phase I results are particularly encouraging because the fullerene photosensitizers were effective at low concentrations and needed only low levels of illumination. In addition, under conditions where bacterial cells were killed, mammalian cells were unharmed. Tests also showed that the fullerene photosensitizers performed substantially better than an antimicrobial photosensitizer commonly used in clinical practice. In the Phase II study, an understanding of the relationship between the nanoscale properties of fullerenes and their ability to selectively photoinactivate microorganisms will be developed, leading to the commercial development of treatments for localized bacterial and fungal infections. In addition, the PS will be tested for the mediation of topical PDT in mouse models of infected wounds and burns using bioluminescent bacteria and low-light imaging to follow infection progress in real time. Antimicrobial photodynamic therapy can serve as a new technique to combat pathogenic bacteria that have developed antibiotic resistance. Wound infections affect millions of Americans each year. With ever increasing antibiotic resistance, antimicrobials are sought for treatment of localized infections (bacterial and fungal) with applications in dermatology, dentistry, and ophthalmology. A global market of $3 billion dollars is projected, representing a significant opportunity for commercialization.
描述(由申请人提供):富勒烯是一类完全由碳原子组成的闭笼纳米材料。大量的注意力集中在开发这些独特分子的医疗用途上。该建议涉及富勒烯在抗菌光动力疗法中的发展,这是一种非侵入性的方法,将无毒光敏剂与无害的可见光结合起来杀死微生物细胞。光动力疗法的一个优点是它的高选择性。这是通过使用选择性靶向特定细胞类型的光敏剂和通过控制照射区域来实现的。在第一阶段的研究中,合成并测试了一些具有非常理想性能的富勒烯基光敏剂。PS灭活广泛的微生物(革兰氏阳性菌,革兰氏阴性菌和真菌减少6对数)。第一阶段的结果特别令人鼓舞,因为富勒烯光敏剂在低浓度下有效,只需要低水平的照明。此外,在细菌细胞被杀死的条件下,哺乳动物细胞没有受到伤害。试验还表明,富勒烯光敏剂的性能大大优于临床实践中常用的抗菌光敏剂。在第二阶段的研究中,富勒烯的纳米级特性与其选择性光灭活微生物的能力之间的关系将得到发展,从而导致局部细菌和真菌感染治疗的商业化发展。此外,PS将在感染伤口和烧伤的小鼠模型中进行局部PDT介导测试,使用生物发光细菌和低光成像来实时跟踪感染进展。抗菌光动力疗法可以作为一种新的技术来对抗已经产生抗生素耐药性的致病菌。伤口感染每年影响数百万美国人。随着抗生素耐药性的不断增加,抗菌药物被用于治疗局部感染(细菌和真菌),应用于皮肤科、牙科和眼科。预计全球市场将达到30亿美元,这是商业化的重要机会。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Antimicrobial Photodynamic Therapy with Functionalized Fullerenes: Quantitative Structure-activity Relationships.
- DOI:10.4172/2157-7439.1000109
- 发表时间:2011-04-01
- 期刊:
- 影响因子:0
- 作者:Mizuno K;Zhiyentayev T;Huang L;Khalil S;Nasim F;Tegos GP;Gali H;Jahnke A;Wharton T;Hamblin MR
- 通讯作者:Hamblin MR
Photodynamic therapy with a cationic functionalized fullerene rescues mice from fatal wound infections.
- DOI:10.2217/nnm.10.98
- 发表时间:2010-12
- 期刊:
- 影响因子:0
- 作者:Lu Z;Dai T;Huang L;Kurup DB;Tegos GP;Jahnke A;Wharton T;Hamblin MR
- 通讯作者:Hamblin MR
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Sanjiv Lalwani其他文献
Sanjiv Lalwani的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Sanjiv Lalwani', 18)}}的其他基金
Antimicrobial Microbead Containing Topical Gel for Burn Wound Disinfection
用于烧伤创面消毒的含有抗菌微珠的外用凝胶
- 批准号:
8877400 - 财政年份:2014
- 资助金额:
$ 40万 - 项目类别:
Antimicrobial Microbead Containing Topical Gel for Burn Wound Disinfection
用于烧伤创面消毒的含有抗菌微珠的外用凝胶
- 批准号:
8776654 - 财政年份:2014
- 资助金额:
$ 40万 - 项目类别:
Delayed Onset of Biofilm Formation and CAUTI with Superhydrophobic Catheters
使用超疏水导管延迟生物膜形成和 CAUTI 的发生
- 批准号:
8251454 - 财政年份:2011
- 资助金额:
$ 40万 - 项目类别:
相似海外基金
Metagenomic discovery and optimization of novel endolysins targeting Cutibacterium acnes to treat acne vulgaris
针对痤疮皮肤杆菌治疗寻常痤疮的新型内溶素的宏基因组发现和优化
- 批准号:
10821291 - 财政年份:2023
- 资助金额:
$ 40万 - 项目类别:
Selective CYP26 inhibitors for the oral treatment of recalcitrant nodular acne.
用于口服治疗顽固性结节性痤疮的选择性 CYP26 抑制剂。
- 批准号:
10822482 - 财政年份:2023
- 资助金额:
$ 40万 - 项目类别:
Developing a novel medical-grade microneedle patch to treat acne vulgaris
开发一种新型医用级微针贴片来治疗寻常痤疮
- 批准号:
10053162 - 财政年份:2023
- 资助金额:
$ 40万 - 项目类别:
Collaborative R&D
ENLIGHT : Light-sensitive Engineered Living Material for acne therapy
ENLIGHT:用于痤疮治疗的光敏工程活性材料
- 批准号:
EP/Y03029X/1 - 财政年份:2023
- 资助金额:
$ 40万 - 项目类别:
Fellowship
Smart Photodynamic Therapy for Acne by Reversibly Switchable Intersystem Crossing in Pure Organic Materials
通过纯有机材料中的可逆可切换系间交叉来治疗痤疮的智能光动力疗法
- 批准号:
10483461 - 财政年份:2022
- 资助金额:
$ 40万 - 项目类别:
Th17 extracellular trap-mediated antimicrobial host defense in acne vulgaris
寻常痤疮中 Th17 细胞外陷阱介导的抗菌宿主防御
- 批准号:
10502200 - 财政年份:2022
- 资助金额:
$ 40万 - 项目类别:
Th17 extracellular trap-mediated antimicrobial host defense in acne vulgaris
寻常痤疮中 Th17 细胞外陷阱介导的抗菌宿主防御
- 批准号:
10698121 - 财政年份:2022
- 资助金额:
$ 40万 - 项目类别:
Acne: a disease of lipid metabolism, microbiome and the immune response
痤疮:一种脂质代谢、微生物组和免疫反应疾病
- 批准号:
10404440 - 财政年份:2022
- 资助金额:
$ 40万 - 项目类别:
Acne: a disease of lipid metabolism, microbiome and the immune response
痤疮:一种脂质代谢、微生物组和免疫反应疾病
- 批准号:
10404436 - 财政年份:2022
- 资助金额:
$ 40万 - 项目类别:
Study of colonization mechanism of high pathogenic Cutibacterium acnes in patients with acne and healthy individuals
高致病性痤疮皮肤杆菌在痤疮患者和健康个体中的定植机制研究
- 批准号:
21K15303 - 财政年份:2021
- 资助金额:
$ 40万 - 项目类别:
Grant-in-Aid for Early-Career Scientists